These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 39085869)

  • 1. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
    Hozumi H; Miyashita K; Nakatani E; Inoue Y; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Inui N; Suda T
    Respir Res; 2024 Jul; 25(1):293. PubMed ID: 39085869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of antifibrotic use on long-term clinical outcomes in the pulmonary fibrosis foundation registry.
    Lee CT; Hao W; Burg CA; Best J; Kolenic GE; Strek ME
    Respir Res; 2024 Jun; 25(1):255. PubMed ID: 38907239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Antifibrotic Use on Mortality in Patients with Idiopathic Pulmonary Fibrosis.
    Xu H; Hui SL; Lee JS; Zhang Z; Boente RD
    Ann Am Thorac Soc; 2024 Oct; 21(10):1407-1415. PubMed ID: 39012168
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis.
    Belhassen M; Dalon F; Nolin M; Van Ganse E
    Respir Res; 2021 May; 22(1):135. PubMed ID: 33947414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
    Suzuki Y; Mori K; Aono Y; Kono M; Hasegawa H; Yokomura K; Naoi H; Hozumi H; Karayama M; Furuhashi K; Enomoto N; Fujisawa T; Nakamura Y; Inui N; Nakamura H; Suda T
    BMC Pulm Med; 2021 Jul; 21(1):221. PubMed ID: 34247593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study.
    Marijic P; Schwarzkopf L; Schwettmann L; Ruhnke T; Trudzinski F; Kreuter M
    Respir Res; 2021 Oct; 22(1):268. PubMed ID: 34666765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
    Kim JS; Murray S; Yow E; Anstrom KJ; Kim HJ; Flaherty KR; Martinez FJ; Noth I
    Chest; 2024 May; 165(5):1163-1173. PubMed ID: 38030064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment.
    Noor S; Nawaz S; Chaudhuri N
    Adv Ther; 2021 Jan; 38(1):268-277. PubMed ID: 33098554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments.
    Fleetwood K; McCool R; Glanville J; Edwards SC; Gsteiger S; Daigl M; Fisher M
    J Manag Care Spec Pharm; 2017 Mar; 23(3-b Suppl):S5-S16. PubMed ID: 28287346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis.
    Mooney J; Reddy SR; Chang E; Broder MS; Gokhale S; Corral M
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1724-1733. PubMed ID: 34818092
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
    Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
    Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications.
    Kelly BT; Thao V; Dempsey TM; Sangaralingham LR; Payne SR; Teague TT; Moua T; Shah ND; Limper AH
    BMC Pulm Med; 2021 Jul; 21(1):239. PubMed ID: 34273943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis.
    Cilli A; Uzer F; Sevinç C; Coşkun F; Ursavaş A; Öner Ş; Kose F
    Pulm Pharmacol Ther; 2021 Dec; 71():102099. PubMed ID: 34793978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of nintedanib and pirfenidone on lung function and survival in patients with idiopathic pulmonary fibrosis in real-life setting.
    Santos G; Fabiano A; Mota PC; Rodrigues I; Carvalho D; Melo N; Novais-Bastos H; Alexandre AT; Moura CS; Guimarães S; Pereira JM; Carvalho A; Morais A
    Pulm Pharmacol Ther; 2023 Dec; 83():102261. PubMed ID: 37758002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparities in Antifibrotic Medication Utilization Among Veterans With Idiopathic Pulmonary Fibrosis.
    Kaul B; Lee JS; Petersen LA; McCulloch C; Rosas IO; Bandi VD; Zhang N; DeDent AM; Collard HR; Whooley MA
    Chest; 2023 Aug; 164(2):441-449. PubMed ID: 36801465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of reduction in antifibrotic treatment on mortality in idiopathic pulmonary fibrosis.
    Porse S; Hoyer N; Shaker SB
    Respir Med; 2022; 204():107015. PubMed ID: 36347111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.